TOT BIOPHARM International Company Limited, an investment holding company, engages in the research, development, manufacturing, and marketing of anti-tumor drugs in China. The company develops TAB008 for the treatment of non-squamous non-small-cell lung cancer, metastatic colorectal cancer, glioblastoma multiforme, ovarian cancer, cervical cancer, fallopian tube cancer, or primary peritoneal cancer, and hepatocellular carci